Actalycabtagene autoleucel

N/A

Report date: 2026/03/31 20:00:21

Base Information

Drug NameActalycabtagene autoleucel
Drug Alias NameActaly-celTalicabtagene autoleucelNexCAR19HCAR19
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[6] 
Global Approved IndicationsLymphoma, B-CellLeukemia, B-Cell
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2023/10/13
Country/TerritoryIndia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesImmunoACT Ltd
China Registration ClassN/A

Develop Information

Active CompaniesImmunoACT LtdHealth Institutes of Turkey
Inactive CompaniesN/A
Active IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A